Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$3.24 +1.4%	$3.35	$2.71 ▼ $4.73	$620.55M	1.2	961,096 shs	354,262 shs
FBIO Fortress Biotech	$1.91 +4.3%	$1.82	$1.33 ▼ $2.89	$55.59M	1.75	412,266 shs	180,983 shs
MEIP MEI Pharma	$2.84 +18.1%	$2.23	$1.46 ▼ $4.10	N/A	0.19	44,443 shs	53,769 shs
NXTC NextCure	$0.44 +2.0%	$0.48	$0.22 ▼ $1.82	$12.22M	1.06	127,114 shs	86,057 shs
TRVN Trevena	$0.94 -14.5%	$1.12	$0.73 ▼ $7.85	$901K	0.61	2,112 shs	126 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	0.00%	+3.35%	-4.85%	+0.15%	+2.37%
FBIO Fortress Biotech	0.00%	+4.89%	+1.54%	+25.59%	+8.47%
MEIP MEI Pharma	0.00%	+1.25%	+31.86%	+41.75%	+0.53%
NXTC NextCure	0.00%	-2.89%	-11.81%	+12.02%	-72.17%
TRVN Trevena	0.00%	-15.32%	-10.65%	-21.67%	-81.93%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABUS Arbutus Biopharma	1.6125 of 5 stars	3.5	0.0	0.0	0.6	2.5	0.6
FBIO Fortress Biotech	2.1434 of 5 stars	3.5	1.0	0.0	0.6	3.3	0.6
MEIP MEI Pharma	2.5416 of 5 stars	0.0	5.0	4.2	0.0	0.8	1.3
NXTC NextCure	4.129 of 5 stars	3.5	3.0	4.3	0.0	1.7	1.3
TRVN Trevena	1.6276 of 5 stars	3.0	4.0	0.0	0.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	3.00	Buy	$5.50	70.02% Upside
FBIO Fortress Biotech	3.00	Buy	$21.00	1,000.05% Upside
MEIP MEI Pharma	2.00	Hold	N/A	N/A
NXTC NextCure	3.00	Buy	$3.50	700.92% Upside
TRVN Trevena	2.00	Hold	$5.00	431.91% Upside

Current Analyst Ratings Breakdown

Latest ABUS, TRVN, NXTC, MEIP, and FBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/1/2025	NXTC NextCure	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$6.17M	100.42	N/A	N/A	$0.51 per share	6.34
FBIO Fortress Biotech	$57.67M	0.98	N/A	N/A	($0.06) per share	-31.82
MEIP MEI Pharma	$65.30M	N/A	$6.30 per share	0.45	$4.96 per share	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	$2.34 per share	N/A
TRVN Trevena	$443K	2.03	N/A	N/A	($11.07) per share	-0.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$69.92M	-$0.41	N/A	N/A	N/A	-1,196.64%	-75.51%	-55.81%	8/7/2025 (Estimated)
FBIO Fortress Biotech	-$46M	-$2.23	N/A	N/A	N/A	-71.24%	-4,712.53%	-27.67%	8/12/2025 (Estimated)
MEIP MEI Pharma	$17.78M	-$4.75	N/A	N/A	N/A	N/A	-77.00%	-64.79%	9/17/2025 (Estimated)
NXTC NextCure	-$55.65M	-$1.76	N/A	N/A	N/A	N/A	-70.16%	-58.10%	7/30/2025 (Estimated)
TRVN Trevena	-$40.29M	-$47.04	N/A	N/A	N/A	N/A	N/A	-119.55%	8/6/2025 (Estimated)

Latest ABUS, TRVN, NXTC, MEIP, and FBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ABUS Arbutus Biopharma	-$0.09	-$0.13	-$0.04	-$0.13	$2.54 million	$1.76 million
5/13/2025	Q3 2025	MEIP MEI Pharma	N/A	-$0.39	N/A	-$0.39	N/A	N/A
5/1/2025	Q1 2025	NXTC NextCure	-$0.40	-$0.39	+$0.01	-$0.39	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
FBIO Fortress Biotech	N/A	N/A	N/A	N/A	N/A
MEIP MEI Pharma	N/A	N/A	N/A	N/A	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	N/A
TRVN Trevena	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	0.04	6.01	6.01
FBIO Fortress Biotech	1.74	1.72	1.55
MEIP MEI Pharma	N/A	16.78	16.78
NXTC NextCure	N/A	10.26	10.26
TRVN Trevena	N/A	2.42	2.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
FBIO Fortress Biotech	96.51%
MEIP MEI Pharma	52.38%
NXTC NextCure	42.65%
TRVN Trevena	13.56%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	20.30%
FBIO Fortress Biotech	27.90%
MEIP MEI Pharma	3.12%
NXTC NextCure	17.90%
TRVN Trevena	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	191.53 million	152.65 million	Optionable
FBIO Fortress Biotech	170	29.57 million	21.32 million	Optionable
MEIP MEI Pharma	100	N/A	N/A	Optionable
NXTC NextCure	90	28.05 million	23.03 million	Optionable
TRVN Trevena	40	959,000	841,000	Optionable

ABUS, TRVN, NXTC, MEIP, and FBIO Headlines

Recent News About These Companies

Trevena, Inc. (TRVN) - Yahoo Finance

June 29, 2025 | finance.yahoo.com

Trevena Enters Securities Exchange Agreement with Investor

May 15, 2025 | tipranks.com

Berks sports roundup: Alex Trevena helps Conrad Weiser to 8-5 softball win

April 11, 2025 | readingeagle.comR

Vanessa Hudgens and Oliver Trevena Appear at Expo West for Caliwater

March 9, 2025 | msn.com

JMP Securities downgrades Trevena (TRVN) to a Hold

December 27, 2024 | markets.businessinsider.com

‘Plane’ Actor Oliver Trevena Signs With Untitled Entertainment

December 16, 2024 | yahoo.com

Lyme Regis town councillor John Trevena stand down

December 11, 2024 | bridportnews.co.ukB

Trevena (TRVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

December 10, 2024 | zacks.com

Trevena appoints new financial chief

November 29, 2024 | investing.com

Trevena Appoints Katrine Sutton as New CFO

November 27, 2024 | tipranks.com

HC Wainwright & Co. Downgrades Trevena (TRVN)

November 16, 2024 | msn.com

Trevena, Inc. Navigates Financial Challenges and Strategic Changes

November 9, 2024 | msn.com

Chester County biopharm firm's latest layoffs impact its C-suite

November 7, 2024 | bizjournals.com

Trevena teeters in dangerous territory, terminating CEO and other execs amid strategic review

November 7, 2024 | fiercebiotech.comF

Trevena Reports Third Quarter 2024 Results and Provides Business Update

November 7, 2024 | globenewswire.com

Why Trevena (TRVN) Stock Is Down 43% Today

October 8, 2024 | msn.com

Trevena, Inc. Faces Delisting from Nasdaq

October 6, 2024 | msn.com

Trevena Announces Receipt of Nasdaq Delisting Notification

October 4, 2024 | globenewswire.com

Learn to Evaluate (TRVN) using the Charts

September 16, 2024 | news.stocktradersdaily.comN

Trevena (NASDAQ:TRVN) Stock Quotes, Forecast and News Summary

September 12, 2024 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABUS, TRVN, NXTC, MEIP, and FBIO Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$3.24 +0.05 (+1.41%)

Closing price 07/3/2025 03:14 PM Eastern

Extended Trading

$3.24 0.00 (0.00%)

As of 07/3/2025 04:49 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Fortress Biotech NASDAQ:FBIO

$1.91 +0.08 (+4.32%)

As of 07/3/2025 03:36 PM Eastern

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

MEI Pharma NASDAQ:MEIP

$2.84 +0.44 (+18.13%)

Closing price 07/3/2025 03:27 PM Eastern

Extended Trading

$2.71 -0.13 (-4.55%)

As of 07/3/2025 04:10 PM Eastern

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

NextCure NASDAQ:NXTC

$0.44 +0.01 (+2.03%)

As of 07/3/2025 03:52 PM Eastern

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Trevena NASDAQ:TRVN

$0.94 -0.16 (-14.55%)

As of 07/3/2025 12:34 PM Eastern

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time